Source link : https://newshealth.biz/health-news/pd-l1-did-not-predict-immunotherapy-benefit-in-cc/
Findings of the BEATcc trial suggest PD-L1 status is not a reliable biomarker for guiding immunotherapy selection in patients with recurrent or metastatic cervical cancer, potentially simplifying treatment decisions for clinicians managing this patient population. A post-hoc analysis of the phase 3 trial demonstrated that the addition of atezolizumab to chemotherapy plus bevacizumab provided clinical […]
The post PD-L1 Did Not Predict Immunotherapy Benefit in CC first appeared on News Health.
—-
Author : News Health
Publish date : 2025-06-24 17:51:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8